Finance

๋ฒ ํƒ€
๋ชฉ๋ก
์ฃผ์‹ ์—…์ข…
์ข…๋ชฉ ์ฝ”๋“œ
์ข…๋ชฉ ์ฝ”๋“œ
๊ฐ€๊ฒฉ
๋ณ€๋™
๋ณ€๋™๋ฅ (%)
์ถ”์„ธ
์ „์ผ ์ข…๊ฐ€
์‹œ๊ฐ€
๊ณ ๊ฐ€
์ €๊ฐ€
๊ฑฐ๋ž˜๋Ÿ‰
์‹œ๊ฐ€์ด์•ก
SIXB
Materials
SIXB
Materials
SIXB
-0.21%
1,091.51
-2.30
-0.21%
โ€”1,093.811,096.521,100.221,091.51โ€”โ€”
SIXC
Communications
SIXC
Communications
SIXC
+0.22%
610.11
+1.34
+0.22%
โ€”608.77608.77612.97608.77โ€”โ€”
SIXE
Energy
SIXE
Energy
SIXE
-1.34%
1,237.98
-16.83
-1.34%
โ€”1,254.811,253.011,253.871,226.33โ€”โ€”
SIXI
Industrials
SIXI
Industrials
SIXI
-0.93%
1,744.71
-16.40
-0.93%
โ€”1,761.111,764.271,766.881,744.71โ€”โ€”
SIXM
Financials
SIXM
Financials
SIXM
-0.37%
640.18
-2.40
-0.37%
โ€”642.58644.87648.48640.18โ€”โ€”
SIXR
Staples
SIXR
Staples
SIXR
-0.18%
849.58
-1.55
-0.18%
โ€”851.13855.66858.75845.56โ€”โ€”
SIXRE
Real estate
SIXRE
Real estate
SIXRE
-0.23%
217.48
-0.50
-0.23%
โ€”217.98217.98218.65216.88โ€”โ€”
SIXT
Technology
SIXT
Technology
SIXT
+1.52%
3,260.69
+48.86
+1.52%
โ€”3,211.833,227.213,268.383,226.55โ€”โ€”
SIXU
Utilities
SIXU
Utilities
SIXU
-0.69%
942.45
-6.53
-0.69%
โ€”948.98948.58957.83941.97โ€”โ€”
SIXV
Health care
SIXV
Health care
SIXV
-0.52%
1,466.80
-7.72
-0.52%
โ€”1,474.521,479.031,481.041,466.80โ€”โ€”
SIXY
Discretionary
SIXY
Discretionary
SIXY
+0.22%
2,397.50
+5.38
+0.22%
โ€”2,392.122,396.952,421.222,382.32โ€”โ€”
2X1:ETR
Abivax SA
โ‚ฌ96.35
+3.21%
(+3.00) 1D
4์›” 30์ผ, ์˜คํ›„ 5์‹œ 35๋ถ„ 59์ดˆ GMT+2  ·   EUR
๋ชจ๋“  ์ข…๋ชฉ ์ฝ”๋“œ
์ข…๋ชฉ ์ฝ”๋“œ๊ฐ€๊ฒฉ๋ณ€๋™๋ณ€๋™๋ฅ (%)
2X1์˜ ์ฃผ์š” ํ†ต๊ณ„ ์ƒ์„ฑ ์ค‘...
์‹œ๊ฐ€
โ‚ฌ92.40
๊ณ ๊ฐ€
โ‚ฌ96.50
์ €๊ฐ€
โ‚ฌ92.25
์‹œ๊ฐ€์ด์•ก
72.30์–ต
ํ‰๊ท  ๊ฑฐ๋ž˜๋Ÿ‰
1.66์ฒœ
๊ฑฐ๋ž˜๋Ÿ‰
1.32์ฒœ
52์ฃผ ์ตœ๊ณ ๊ฐ€
โ‚ฌ132.20
52์ฃผ ์ตœ์ €๊ฐ€
โ‚ฌ68.10
EPS
-โ‚ฌ4.83
์ง์› ์ˆ˜
69
๋‰ด์Šค ๊ธฐ์‚ฌ
์›น ์†Œ์Šค ๊ธฐ๋ฐ˜
ํ”„๋กœํ•„
Abivax SA is a clinical stage biotechnology company focused on developing innovative treatments that harness the bodyโ€™s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases. Abivax has a program in clinical development with its lead drug candidate, obefazimod, to treat ulcerative colitis. Another program in Crohnโ€™s disease is also in preparation and other potential inflammatory indications are being evaluated. The companyโ€™s headquarters are based in Paris, France with a US office in Waltham, Massachusetts. Abivaxโ€™s Research and development work is conducted at its research center based in Montpellier, France. Wikipedia
Abivax SA์— ๊ด€ํ•œ ์ •๋ณด
CEO๋งˆํฌ ๋“œ ๊ฐ€๋ฆฌ๋ธ | ํ•˜๋ฅดํŠธ๋ฌดํŠธ J. ์—๋ฅผ๋ฆฌํžˆ
์ง์›69
์ฐฝ๋ฆฝ์ผ2013. 12. 4.
๋ณธ์‚ฌ-
์—…์ข…-
์›น์‚ฌ์ดํŠธabivax.com
๋งˆ์ง€๋ง‰ ๋ณด๊ณ ์„œ
2026. 3. 23.
ํšŒ๊ณ„ ๊ธฐ๊ฐ„
Q4 2025
์ •๊ทœํ™”๋œ ์ฃผ๋‹น์ˆœ์ด์ต/์ถ”์ •์น˜
-/ -EUR
์ˆ˜์ต/์˜ˆ์ƒ์น˜
191.40๋งŒ/ (134.63๋งŒ ์˜ˆ์ƒ)EUR
ํšŒ๊ณ„์—ฐ๋„ 2025๋…„ 4๋ถ„๊ธฐ๋ถ„๊ธฐ ์‹ค์  ๋ฐœํ‘œ
์‹ค์  ๋ฐœํ‘œ๋ฅผ ๊ธฐ๋‹ค๋ฆฌ๋Š” ์ค‘
ํ•œ๋ˆˆ์— ๋ณด๊ธฐ์ตœ์‹  ๋‰ด์Šค ๋ฐ ๋ณด๊ณ ์„œ์˜ ํ†ต๊ณ„
์ด์ „ ๋ณด๊ณ ์„œ๋ชจ๋“  ๊ฐ’(ํ†ตํ™”: EUR)
Loading Previous Earnings...
์†์ต ๊ณ„์‚ฐ์„œ
์ˆ˜์ต
์ˆœ์ด์ต
๋ชจ๋“  ๊ฐ’(ํ†ตํ™”: EUR)
2025๋…„ 3์›”
2025๋…„ 6์›”
2025๋…„ 9์›”
2025๋…„ 12์›”
์ˆ˜์ต
97.00๋งŒ
104.70๋งŒ
63.90๋งŒ
191.40๋งŒ
๋งค์ถœ์›๊ฐ€
-
-
-
-
์ˆ˜์ต ๋น„์šฉ
-
-
-
-
์—ฐ๊ตฌ ๊ฐœ๋ฐœ ๋น„์šฉ
3930.10๋งŒ
3864.50๋งŒ
5541.60๋งŒ
4439.90๋งŒ
์ด ์—ฐ๊ตฌ ๊ฐœ๋ฐœ ๋น„์šฉ
-
-
-
-
ํŒ๋งค ๊ด€๋ฆฌ ๋น„์šฉ
889.30๋งŒ
894.40๋งŒ
2733.80๋งŒ
2768.90๋งŒ
์šด์˜ ๋น„์šฉ
4817.00๋งŒ
4754.30๋งŒ
8135.00๋งŒ
7356.20๋งŒ
์ด ์šด์˜ ๋น„์šฉ
4817.00๋งŒ
4754.30๋งŒ
8135.00๋งŒ
7356.20๋งŒ
์˜์—… ์ด์ต
-4720.00๋งŒ
-4649.60๋งŒ
-8071.10๋งŒ
-7164.80๋งŒ
์˜์—… ์™ธ ์ˆ˜์ต
43.10๋งŒ
265.50๋งŒ
-7419.80๋งŒ
-496.00๋งŒ
ํŠน์ • ํ•ญ๋ชฉ์„ ํฌํ•จํ•œ EBT
-5237.00๋งŒ
-4841.40๋งŒ
-1.53์–ต
-7611.20๋งŒ
ํŠน์ • ํ•ญ๋ชฉ์„ ์ œ์™ธํ•œ EBT
-5131.90๋งŒ
-4841.40๋งŒ
-1.53์–ต
-8084.20๋งŒ
๋ฒ•์ธ์„ธ ๋น„์šฉ
-
-
-
584.80๋งŒ
์œ ํšจ ์„ธ์œจ
-
-
-
-7.68%
๊ธฐํƒ€ ์šด์˜ ๋น„์šฉ
-2.40๋งŒ
-4.60๋งŒ
-140.40๋งŒ
147.40๋งŒ
์ˆœ์ด์ต
-5237.00๋งŒ
-4841.40๋งŒ
-1.53์–ต
-8196.00๋งŒ
์ˆœ์ด์ต๋ฅ 
-5,398.97%
-4,624.07%
-23,999.69%
-4,282.13%
์ฃผ๋‹น์ˆœ์ด์ต
-
-
-
-
์ด์ž ๋ฐ ํˆฌ์ž ์†Œ๋“
85.90๋งŒ
19.00๋งŒ
336.10๋งŒ
119.00๋งŒ
์ด์ž ๋น„์šฉ
-453.50๋งŒ
-352.10๋งŒ
-421.30๋งŒ
-1527.40๋งŒ
์ˆœ์ด์ž ๋น„์šฉ
-367.60๋งŒ
-333.10๋งŒ
-85.20๋งŒ
-1408.40๋งŒ
๊ฐ๊ฐ€์ƒ๊ฐ๋น„
-
-
-
-
EBITDA
-4712.10๋งŒ
-4647.30๋งŒ
-8063.10๋งŒ
-7075.80๋งŒ
์ž์‚ฐ ๋งค๊ฐ์œผ๋กœ ์ธํ•œ ์ด์ต ๋˜๋Š” ์†์‹ค
-
-
-
-
AI ์ฝ˜ํ…์ธ ์—๋Š” ์˜ค๋ฅ˜๊ฐ€ ์žˆ์„ ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค. ์ž์„ธํžˆ ์•Œ์•„๋ณด๊ธฐ
๋„์›€๋ง์˜๊ฒฌ ๋ณด๋‚ด๊ธฐ๊ฐœ์ธ ์ •๋ณด ๋ณดํ˜ธ์•ฝ๊ด€๋ฉด์ฑ… ์กฐํ•ญ

์กฐ์‚ฌ

๋‚ด ์ž‘์—…
์•„์ง ๋งŒ๋“  ์ž‘์—…์ด ์—†์Šต๋‹ˆ๋‹ค
์ž‘์—…์ด ์—ฌ๊ธฐ์— ํ‘œ์‹œ๋ฉ๋‹ˆ๋‹ค. ์ž‘์—…์„ ์˜ˆ์•ฝํ•˜๋ฉด ๋ถ€์žฌ์ค‘์ผ ๋•Œ๋„ Google Finance๊ฐ€ ์ž‘์—…์„ ์ฒ˜๋ฆฌํ•ด ์ค๋‹ˆ๋‹ค.
ํ…œํ”Œ๋ฆฟ
๊ด€์‹ฌ ๋ชฉ๋ก ๋ธŒ๋ฆฌํ•‘
๊ด€์‹ฌ ๋ชฉ๋ก์˜ ์ผ์ผ ์žฅ์ „ ๋ถ„์„
์˜ˆ์ •๋œ ์‹ค์  ๋ฐœํ‘œ
์ด๋ฒˆ ์ฃผ์— ์˜ˆ์ •๋œ ์ˆœ์ต ๋ณด๊ณ ์„œ
๋น„์ •์ƒ์ ์ธ ๋ณ€๋™์„ฑ ๋ฐ ๊ฑฐ๋ž˜๋Ÿ‰
์˜ค๋Š˜์˜ ๋ณ€๋™์„ฑ ๋ฐ ๊ฑฐ๋ž˜๋Ÿ‰ ์กฐ๊ธฐ ๊ฒฝ๊ณ 
AI ์ฝ˜ํ…์ธ ์—๋Š” ์˜ค๋ฅ˜๊ฐ€ ์žˆ์„ ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค. ์ž์„ธํžˆ ์•Œ์•„๋ณด๊ธฐ
๋„์›€๋ง์˜๊ฒฌ ๋ณด๋‚ด๊ธฐ๊ฐœ์ธ ์ •๋ณด ๋ณดํ˜ธ์•ฝ๊ด€๋ฉด์ฑ… ์กฐํ•ญ